Share Name Share Symbol Market Type Share ISIN Share Description
Fusion Antibody Plc LSE:FAB London Ordinary Share GB00BDQZGK16 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 77.50p 75.00p 80.00p 77.50p 77.50p 77.50p 0 08:08:44
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology - - - - 17.12

Fusion Antibody Share Discussion Threads

Showing 76 to 99 of 100 messages
Chat Pages: 4  3  2  1
DateSubjectAuthorDiscuss
16/8/2018
09:44
Not able to buy any on HL , anyone else having same problem?
fhasson
13/8/2018
14:57
Timbo , do you think MM are at it here as those big buys are not shifting price up? What's your take? Appreciated
fhasson
13/8/2018
08:05
Holy Moly 40p? who knows? B1
b1tcoin
13/8/2018
08:05
Holy Moly 40p? who knows? B1
b1tcoin
13/8/2018
07:50
Back to the IPO price (82p) today? I see they still state that they have 8 out of the top 10 pharmas as customers in today's RNS, so presumably the one they lost in March, is not one of the eight For reference, Allenby's last market forecast was back in March with the share price standing at 125p/share (market cap £27.6m): http://www.allenbycapital.com/research/research-FAB.html
timbo003
13/8/2018
07:10
Sales less than expected cos we lied and cheated our way to ipo Running out of cash soon 70p today
opodio
20/6/2018
13:53
Only one customer exceeds 10% of income (10.4%) so worst case scenario if they left would be 10.4% lost. One doesn't know if they are that largest company .perhaps timbo has the answer to that question ?
haroldthegreat
20/6/2018
13:27
what % of income is from mab discovery ? Amati doubled their investment 6 weeks ago and i am sure they did due diligence before doing so.they must have known about contract renewal dates and wouldnt have purchased if this was a potential problem.
haroldthegreat
06/6/2018
22:00
It's like -wall - talking - and brick
fhasson
06/6/2018
21:58
https://www.fusionantibodies.com/blog/2018/june/fusion-antibodies-partners-with-protein-alternatives
fhasson
13/5/2018
20:41
Hopefully some positive share movement with new pancreatic cancer cell antibody work with fusion and QUB
fhasson
13/5/2018
20:39
https://t.co/NeZxTCJEHj?amp=1
fhasson
03/5/2018
23:23
Appreciate your feedback timbo003 over the coming weekend and will check the website too. Good to see the past few weeks share price appears to be ticking up,which may well be down to increased business deals / interest in this emerging area of medicine. Also holding OXB in my portfolio which am very excited about and recognise FAB as being in the same chess game of chronic disease management and immuno-oncology.F
fhasson
03/5/2018
22:03
>>>>Fhasson I would estimate that there were around 20 - 25 attendees and it a very informative meeting with many interesting questions during the Q&A (not just from me!). I will endeavor to write up a few notes at the weekend, meanwhile I have asked if the slide deck used last night could go up on the FAB web site although it hasn't gone up yet as far as I can see.
timbo003
03/5/2018
21:45
Any update on the investors meeting on Wednesday Timbo?
fhasson
25/4/2018
11:32
This is a post from Walbrook PR, we provide financial PR & IR services for Fusion Antibodies. As a reminder we are organising an investor event for the Company, details below. If you would like to attend please email Walbrook PR on - fusion@walbrookpr.com - rather than replying to this post. Thank you. Fusion Antibodies will be hosting an investor presentation on Wednesday 2 May 2018. The briefing by Paul Kerr, CEO of Fusion will take place at Copper Bar, Balls Brothers, 6 Adams Court, Old Broad Street, EC2N 1DX from 4.30pm for a 4.45pm start and will be followed by drinks and networking. If you would like to register to attend, please contact Walbrook PR on 020 7933 8780 or email fusion@walbrookpr.com.
walbrook2
23/4/2018
16:23
Unfortunately cannot make it but keep us informed. Hopefully some good news awaits us!
fhasson
23/4/2018
11:31
I received this E mail from Walbrook this morning, I shall definitely go along Fusion Antibodies (AIM: FAB), a contract research organization providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, announces that it will hold a presentation for investors on Wednesday, 2 May 2018. The briefing by Paul Kerr, CEO of Fusion will take place at Copper Bar, Balls Brothers, 6 Adams Court, Old Broad Street, EC2N 1DX from 4.30pm for a 4.45pm start and will be followed by drinks and networking. If you would like to register to attend, please reply to: fusion@walbrookpr.com
timbo003
10/4/2018
17:59
Dealers trying to attract business. Otherwise zzzzzz
wetdream
28/3/2018
17:16
Anyone know why price goes down on buys and no sells???
fhasson
26/3/2018
19:47
Very little but that will change.
fhasson
26/3/2018
17:35
No interest in this co. Is there?
wetdream
05/3/2018
22:24
Held well considering a profit warning
fhasson
05/3/2018
09:27
Probably came to market a bit too soon.
wetdream
Chat Pages: 4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180821 08:18:40